Suppr超能文献

美国妇产科医师学会委员会意见第 494 号:磺胺类药物、呋喃妥因与出生缺陷风险。

ACOG Committee Opinion No. 494: Sulfonamides, nitrofurantoin, and risk of birth defects.

出版信息

Obstet Gynecol. 2011 Jun;117(6):1484-1485. doi: 10.1097/AOG.0b013e3182238c57.

Abstract

The evidence regarding an association between the nitrofuran and sulfonamide classes of antibiotics and birth defects is mixed. As with all patients, antibiotics should be prescribed for pregnant women only for appropriate indications and for the shortest effective duration. During the second and third trimesters, sulfonamides and nitrofurantoins may continue to be used as first-line agents for the treatment and prevention of urinary tract infections and other infections caused by susceptible organisms. Prescribing sulfonamides or nitrofurantoin in the first trimester is still considered appropriate when no other suitable alternative antibiotics are available. Pregnant women should not be denied appropriate treatment for infections because untreated infections can commonly lead to serious maternal and fetal complications.

摘要

关于硝基呋喃类和磺胺类抗生素与出生缺陷之间的关联,现有证据相互矛盾。与所有患者一样,只有在适当的指征下,且为了达到最有效的治疗时长,才应对孕妇开具抗生素。在妊娠第二和第三个三个月,磺胺类药物和硝基呋喃类药物仍可作为治疗和预防泌尿道感染和其他敏感病原体感染的一线药物。如果没有其他合适的替代抗生素,在妊娠第一三个月仍可考虑开磺胺类药物或硝基呋喃类药物。不应因为感染未经治疗可能会导致严重的母亲和胎儿并发症,而拒绝孕妇接受适当的治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验